Acrolein, an a,b-unsaturated aldehyde, irreversibly inhibits the acetylation of aromatic amine xenobiotics by human arylamine n-acetyltransferase 1

Drug Metabolism and Disposition

Volumn 41, Issue 7, 2013, Pages 1300-1305

  Bui, Linh C ^a   Manaa, Amine ^a   Xu, Ximing ^a   Duval, Romain ^a   Busi, Florent ^a   Dupret, Jean Marie ^a   Rodrigues Lima, Fernando ^a   Dairou, Julien ^a  

^a Groupe Hospitalier Pitié Salpêtrière   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; ACROLEIN; ALDEHYDE; ALPHA BETA UNSATURATED ALDEHYDE; ARYLAMINE ACETYLTRANSFERASE; GLUTATHIONE; UNCLASSIFIED DRUG; ISOENZYME; N-ACETYLTRANSFERASE 1; XENOBIOTIC AGENT; N ACETYLTRANSFERASE 1;

ACETYLATION; ARTICLE; CATALYSIS; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME KINETICS; ENZYME METABOLISM; ENZYME PURIFICATION; ENZYME SYNTHESIS; EPITHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL; SMOKING; XENOBIOTIC METABOLISM; ANTAGONISTS AND INHIBITORS; KINETICS; METABOLISM; DRUG ANTAGONISM;

NICOTIANA TABACUM;

ACETYLATION; ACROLEIN; ARYLAMINE N-ACETYLTRANSFERASE; CELLS, CULTURED; HUMANS; ISOENZYMES; KINETICS; XENOBIOTICS;

EID: 84879097544     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052258     Document Type: Article

References (30)

1. Agúndez JA (2008) Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 9:520-531.
2. Butcher NJ, Tiang J, and Minchin RF (2008) Regulation of arylamine N-acetyltransferases. Curr Drug Metab 9:498-504.
3. Cai J, Bhatnagar A, and Pierce WM, Jr (2009) Protein modification by acrolein: Formation and stability of cysteine adducts. Chem Res Toxicol 22:708-716.
4. Carbone DL, Doorn JA, Kiebler Z, and Petersen DR (2005) Cysteine modification by lipid peroxidation products inhibits protein disulfide isomerase. Chem Res Toxicol 18:1324-1331.
5. Cornish-Bowden A (2001) Fundamentals of Enzyme Kinetics, Portland Press, London.
6. Dairou J, Atmane N, Rodrigues-Lima F, and Dupret JM (2004) Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: A cellular and mechanistic study. J Biol Chem 279:7708-7714.
7. Dairou J, Petit E, Ragunathan N, Baeza-Squiban A, Marano F, Dupret JM, and Rodrigues-Lima F (2009) Arylamine N-acetyltransferase activity in bronchial epithelial cells and its inhibition by cellular oxidants. Toxicol Appl Pharmacol 236:366-371.
8. Feng Z, Hu W, Hu Y, and Tang MS (2006) Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci USA 103:15404-15409.
9. Grant DM (1993) Molecular genetics of the N-acetyltransferases. Pharmacogenetics 3:45-50.
10. Grant DM, Blum M, Beer M, and Meyer UA (1991) Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184-191.
11. Hein DW, McQueen CA, Grant DM, Goodfellow GH, Kadlubar FF, and Weber WW (2000) Pharmacogenetics of the arylamine N-acetyltransferases: A symposium in honor of Wendell W. Weber. Drug Metab Dispos 28:1425-1432.
12. Hein DW (1988) Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948:37-66.
13. Jia L, Liu Z, Sun L, Miller SS, Ames BN, Cotman CW, and Liu J (2007) Acrolein, a toxicant in cigarette smoke, causes oxidative damage and mitochondrial dysfunction in RPE cells: Protection by (R)-alpha-lipoic acid. Invest Ophthalmol Vis Sci 48:339-348.
14. Kehrer JP and Biswal SS (2000) The molecular effects of acrolein. Toxicol Sci 57:6-15.
15. Kim D and Guengerich FP (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol 45:27-49.
16. Lambert C, McCue J, Portas M, Ouyang Y, Li J, Rosano TG, Lazis A, and Freed BM (2005) Acrolein in cigarette smoke inhibits T-cell responses. J Allergy Clin Immunol 116:916-922.
17. Liu L, Wagner CR, and Hanna PE (2008) Human arylamine N-acetyltransferase 1: In vitro and intracellular inactivation by nitrosoarene metabolites of toxic and carcinogenic arylamines. Chem Res Toxicol 21:2005-2016.
18. Luo J, Hill BG, Gu Y, Cai J, Srivastava S, Bhatnagar A, and Prabhu SD (2007) Mechanisms of acrolein-induced myocardial dysfunction: Implications for environmental and endogenous aldehyde exposure. Am J Physiol Heart Circ Physiol 293:H3673-H3684.
19. Martyniuk CJ, Fang B, Koomen JM, Gavin T, Zhang L, Barber DS, and Lopachin RM (2011) Molecular mechanism of glyceraldehyde-3-phosphate dehydrogenase inactivation by a,b-unsaturated carbonyl derivatives. Chem Res Toxicol 24:2302-2311.
20. Myers CR and Myers JM (2009) The effects of acrolein on peroxiredoxins, thioredoxins, and thioredoxin reductase in human bronchial epithelial cells. Toxicology 257:95-104.
21. Nakamura M, Tomitori H, Suzuki T, Sakamoto A, Terui Y, Saiki R, Dohmae N, Igarashi K, and Kashiwagi K (2013) Inactivation of GAPDH as one mechanism of acrolein toxicity. Biochem Biophys Res Commun 430:1265-1271.
22. National Toxicology Program (NTP) (2011) 12th Report on Carcinogens, U.S. Department of Health and Human Services, Public Health Service, Research Triangle Park, NC.
23. Ragunathan N, Dairou J, Pluvinage B, Martins M, Petit E, Janel N, Dupret JM, and Rodrigues-Lima F (2008) Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: Molecular and cellular mechanisms of inhibition. Mol Pharmacol 73:1761-1768.
24. Rodrigues-Lima F, Dairou J, and Dupret JM (2008) Effect of environmental substances on the activity of arylamine N-acetyltransferases. Curr Drug Metab 9:505-509.
25. Seiner DR, LaButti JN, and Gates KS (2007) Kinetics and mechanism of protein tyrosine phosphatase 1B inactivation by acrolein. Chem Res Toxicol 20:1315-1320.
26. Sim E, Lack N, Wang CJ, Long H, Westwood I, Fullam E, and Kawamura A (2008) Arylamine N-acetyltransferases: Structural and functional implications of polymorphisms. Toxicology 254: 170-183.
27. Spiess PC, Deng B, Hondal RJ, Matthews DE, and van der Vliet A (2011) Proteomic profiling of acrolein adducts in human lung epithelial cells. J Proteomics 74:2380-2394.
28. Tirumalai R, Rajesh Kumar T, Mai KH, and Biswal S (2002) Acrolein causes transcriptional induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549) cells. Toxicol Lett 132:27-36.
29. Wu HC, Lu HF, Hung CF, and Chung JG (2000) Inhibition by vitamin C of DNA adduct formation and arylamine N-acetyltransferase activity in human bladder tumor cells. Urol Res 28:235-240.
30. Zhang JY, Wang Y, and Prakash C (2006) Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 7:939-948.